ABSTRACT
As in other areas of the health system, COVID-19 has had a dramatic impact on hospital compounding. This area has faced numerous challenges, including the shortage of frequent-use products (hydroalcoholic solutions, lopinavir/ritonavir suspension), the use of new preparations for SARS-CoV-2 (tocilizumab, remdesivir), or requests from overwhelmed wards unable to assume the safe preparation of a high volume of medications (intravenous solutions). The demand for all types of preparations (topic and oral medications, intravenous solutions) has increased dramatically. This increase has highlighted the shortage of resources allocated to this area, which has made it difficult to meet the high demand for preparations. In addition, the pandemic has revealed the scarcity of research on such basic aspects as agent stability and drug compatibility. One of the most relevant conclusions drawn from the COVID-19 pandemic is that the basic areas of hospital pharmacy, along with other, must be maintained and reinforced, as these are the areas that make us essential.
Como todo el sector sanitario, la farmacotecnia hospitalaria ha sufrido el impacto de la pandemia de la COVID-19, enfrentándose a la necesidad de cubrir el desabastecimiento de productos de uso frecuente (soluciones hidroalcohólicas, lopinavir/ritonavir suspensión), a nuevas preparaciones surgidas de las nuevas necesidades provocadas por el SARS-CoV-2 (tocilizumab, remdesivir), o a peticiones de plantas desbordadas por la carga asistencial, incapaces de asumir con un mínimo de seguridad la preparación de numerosos medicamentos (mezclas intravenosas). El incremento de actividad ha sido en todo tipo de preparados (tópicos, orales y mezclas intravenosas) y ha puesto de manifiesto la escasez de recursos destinados a esta área, que se ha traducido en serios problemas para afrontar todas las elaboraciones necesarias, así como la falta de investigación en aspectos tan básicos como la estabilidad o la compatibilidad de medicamentos. Probablemente, una de las conclusiones más importantes que podemos extraer tras la COVID-19 es que sin menospreciar otras áreas de la farmacia hospitalaria que también deben desarrollarse debemos mantener y potenciar las áreas básicas de nuestra profesión. Aquellas que nos hacen imprescindibles.
Subject(s)
Betacoronavirus , Coronavirus Infections/drug therapy , Drug Compounding , Pandemics , Pharmacy Service, Hospital/organization & administration , Pneumonia, Viral/drug therapy , Administration, Oral , Antiviral Agents/supply & distribution , Antiviral Agents/therapeutic use , Blood Component Transfusion , COVID-19 , Disinfection , Drug Administration Routes , Drug Interactions , Drug Stability , Equipment Contamination/prevention & control , Excipients , Forecasting , Home Care Services , Humans , Hydroxychloroquine/administration & dosage , Hydroxychloroquine/chemistry , Infusions, Intravenous , Lopinavir/administration & dosage , Personal Protective Equipment/supply & distribution , Platelet-Rich Plasma , Ritonavir/administration & dosage , SARS-CoV-2 , Solutions , COVID-19 Drug TreatmentABSTRACT
Como todo el sector sanitario, la farmacotecnia hospitalaria ha sufrido el impacto de la pandemia de la COVID-19, enfrentándose a la necesidad de cubrir el desabastecimiento de productos de uso frecuente (soluciones hidroalcohólicas, lopinavir/ritonavir suspensión), a nuevas preparaciones surgidas de las nuevas necesidades provocadas por el SARS-CoV-2 (tocilizumab, remdesivir), o a peticiones de plantas desbordadas por la carga asistencial, incapaces de asumir con un mínimo de seguridad la preparación de numerosos medicamentos (mezclas intravenosas). El incremento de actividad ha sido en todo tipo de preparados (tópicos, orales y mezclas intravenosas) y ha puesto de manifiesto la escasez de recursos destinados a esta área, que se ha traducido en serios problemas para afrontar todas las elaboraciones necesarias, así como la falta de investigación en aspectos tan básicos como la estabilidad o la compatibilidad de medicamentos. Probablemente, una de las conclusiones más importantes que podemos extraer tras la COVID-19 es que -sin menospreciar otras áreas de la farmacia hospitalaria que también deben desarrollarse- debemos mantener y potenciar las áreas básicas de nuestra profesión. Aquellas que nos hacen imprescindibles
As in other areas of the health system, COVID-19 has had a dramatic impact on hospital compounding. This area has faced numerous challenges, including the shortage of frequent-use products (hydroalcoholic solutions, lopinavir/ritonavir suspension), the use of new preparations for SARS-CoV-2 (tocilizumab, remdesivir), or requests from overwhelmed wards unable to assume the safe preparation of a high volume of medications (intravenous solutions). The demand for all types of preparations (topic and oral medications, intravenous solutions) has increased dramatically. This increase has highlighted the shortage of resources allocated to this area, which has made it difficult to meet the high demand for preparations. In addition, the pandemic has revealed the scarcity of research on such basic aspects as agent stability and drug compatibility. One of the most relevant conclusions drawn from the COVID-19 pandemic is that the basic areas of hospital pharmacy, along with other, must be maintained and reinforced, as these are the areas that make us essential
Subject(s)
Humans , Betacoronavirus , Coronavirus Infections/drug therapy , Drug Compounding , Pandemics , Pharmacy Service, Hospital/organization & administration , Pneumonia, Viral/drug therapy , Antiviral Agents/supply & distribution , Antiviral Agents/therapeutic use , Blood Component Transfusion , Drug Administration Routes , Drug Interactions , Drug Stability , Equipment Contamination/prevention & control , Infusions, Intravenous , Lopinavir/administration & dosage , Ritonavir/administration & dosageABSTRACT
N-acetylcysteine in combination with urea is effective for the treatment of congenital ichthyosis. Although it is well tolerated, its foul smell may compromise treatment adherence. Carbocysteine is a similar molecule without that bad odor. Thus, we have tried a new formula with carbocysteine for the treatment of 4 patients with ichthyosis, with positive results.
Subject(s)
Anti-Infective Agents, Local/administration & dosage , Carbocysteine/administration & dosage , Ichthyosis/drug therapy , Administration, Topical , Child , Child, Preschool , Drug Combinations , Humans , Male , Middle Aged , Urea/administration & dosageABSTRACT
Topical N-acetylcysteine is gaining recognition as a useful and safe therapy for lamellar ichthyosis. We report a case of inherited lamellar ichthyosis that showed a good response to treatment with a new formula of N-acetylcysteine cream. With this new formula, which is described in the article in a practical manner, the odor of sulfur was minimized and we obtained excellent adherence to treatment.